- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05501522
Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted With AS03 in Adults Aged 18 Years and Older
September 6, 2023 updated by: SK Bioscience Co., Ltd.
A Phase III, Placebo-controlled, Randomized, Observer-blinded, Multi-national, Multi-center Study to Assess the Safety, Reactogenicity, and Immunogenicity of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 in Adults Aged 18 Years and Older
This is a Phase III, randomized, placebo-controlled, observer-blinded, parallel-group, multi-center study to assess the safety, reactogenicity, and immunogenicity of heterologous booster vaccination of SK SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03 in adults aged 18 years and older.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of heterologous booster vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) adjuvanted with AS03 in adults aged 18 years and older.
Study Type
Interventional
Enrollment (Actual)
840
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yoonyeong Lee
- Phone Number: +82 2-2008-2337
- Email: yoonyeong@sk.com
Study Locations
-
-
-
Bogotá, Colombia, 1008
- Policlinico Social del Norte
-
-
Cundinamarca
-
Chía, Cundinamarca, Colombia
- CAIMED (Centro de Atención e Investigación Médica)
-
Contact:
- Reynales Humberto, MD
-
-
-
-
Dhulikhel
-
Kathmandu, Dhulikhel, Nepal, 45200
- Dhulikhel
-
-
Maharajgunj
-
Kathmandu, Maharajgunj, Nepal, 44600
- Institute of Medicine (IOM)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Participant must be 18 years of age and older, at the time of signing the informed consent.
- Participants who are healthy or medically stable as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, and medical judgement of the investigator.
- Participants who are able to attend all scheduled visits and comply with all study procedures.
- Participants who received primary vaccination of 1 of 6 different WHO EUA qualified COVID-19 vaccine (mRNA-1273, ChAdOx1 nCOV-19, Ad26.COV2.S, BNT162b2, BBIBP-CorV, CoronaVac) at least 12 weeks prior to study vaccination, and with no history of other COVID-19 vaccination, including booster doses.
- Participants who have a qualitative test result for antibody to SARS-CoV-2 nucleocapsid proteins at screening for assessment of previous SARS-CoV-2 infection
- Female participants of childbearing potential must agree to be heterosexually inactive, or agree to consistently use at least one acceptable method of contraception from at least 4 weeks prior to the study vaccination to 12 weeks after the study vaccination
- Female participants with a negative urine or serum pregnancy test at screening.
- Capable of giving signed informed consent as described in Appendix 10.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion Criteria:
- Any clinically significant respiratory symptoms (e.g. cough, sore throat), febrile illness (tympanic temperature >38°C), or acute illness within 72 hours prior to the study vaccination. A prospective participant should not be included until 72 hours after the condition has resolved.
- Concurrent or past SARS-CoV-2 infection within 12 weeks prior to the study vaccination confirmed by virological or serological testing
- History of virologically or serologically confirmed SARS, or MERS disease
- History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease.
- History of bleeding disorder or thrombocytopenia which is contraindicating intramuscular vaccination in the investigator's opinion.
- History of hypersensitivity and severe allergic reaction (e.g. anaphylaxis, Guillain-Barre syndrome) to any vaccines or components of the study intervention.
- History of malignancy within 1 year prior to the study vaccination (with the exception of malignancy with minimal risk of recurrence at the discretion of the investigator).
- Significant unstable chronic or acute illness that, in the opinion of the investigator, might pose a health risk to the participant if enrolled, or could interfere with the protocol-specified activities, or interpretation of study results.
- Any other conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g., alcohol or drug abuse, neurologic or psychiatric conditions).
- Female participants who are pregnant or breastfeeding.
- Receipt of any medications or vaccinations intended to prevent COVID-19 except for the pre-defined COVID-19 vaccines expected to be given prior to screening (mRNA-1273, ChAdOx1 nCOV-19, Ad26.COV2.S, BNT162b2, BBIBP-CorV, CoronaVac).
- Receipt of any vaccine within 4 weeks prior to the study vaccination or planned receipt of any vaccine from enrollment through 4 weeks after the study vaccination, except for influenza vaccination, which may be received at least 2 weeks prior to the study vaccination.
- Receipt of immunoglobulins and/or any blood or blood products within 12 weeks prior to the study vaccination.
- Chronic use (more than 2 consecutive weeks) of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (≥10mg prednisone/day or equivalent for more than 2 consecutive weeks) within 12 weeks prior to the study vaccination. The use of topical and nasal glucocorticoids will be permitted.
- Participation in another clinical study and receipt of study intervention within 4 weeks prior to the study vaccination, or concurrent, planned participation in another clinical study with study intervention during the study period.
- Investigators, or study staff who are directly involved in the conduct of this study or supervised by the investigator, and their respective family members.
- Donation of ≥450mL of blood product within 4 weeks prior to screening, or planned donation of blood product during the study period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Primary series of mRNA-1273 manufactured by ModernaTX, Inc.
participants who received primary vaccination of a mRNA-1273 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
|
injection volume of 0.5mL on Day 0
|
Placebo Comparator: Primary series of mRNA-1273 manufactured by ModernaTX, Inc. (Placebo)
participants who received primary vaccination of a mRNA-1273 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
|
injection volume of 0.5mL on Day 0
|
Experimental: Primary series of ChAdOx1 nCOV-19 manufactured by Astrazeneca or S.I of India Pvt., Ltd.
participants who received primary vaccination of a ChAdOx1 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
|
injection volume of 0.5mL on Day 0
|
Placebo Comparator: Primary series of ChAdOx1 nCOV-19 manufactured by Astrazeneca or S.I of India Pvt., Ltd. (Placebo)
participants who received primary vaccination of a ChAdOx1 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
|
injection volume of 0.5mL on Day 0
|
Experimental: A single dose vaccination of Ad26.COV2.S manufactured by Janssen Pharmaceuticals/Johnson & Johnson
participants who received primary vaccination of a Ad26.COV2.S at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
|
injection volume of 0.5mL on Day 0
|
Placebo Comparator: A single dose vaccination of Ad26.COV2.S manufactured by Janssen Pharmaceuticals/J&J (Placebo)
participants who received primary vaccination of a Ad26.COV2.S at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive Placebo.
|
injection volume of 0.5mL on Day 0
|
Active Comparator: Primary series of BNT162b2 manufactured by Pfizer/BioNTech
participants who received primary vaccination of a BNT162b2 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
|
injection volume of 0.5mL on Day 0
|
Placebo Comparator: Primary series of BNT162b2 manufactured by Pfizer/BioNTech (Placebo)
participants who received primary vaccination of a BNT162b2 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
|
injection volume of 0.5mL on Day 0
|
Experimental: Primary series of BBIBP-CorV manufactured by Sinopharm
participants who received primary vaccination of a BBIBP-CorV at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
|
injection volume of 0.5mL on Day 0
|
Placebo Comparator: Primary series of BBIBP-CorV manufactured by Sinopharm (Placebo)
participants who received primary vaccination of a BBIBP-CorV at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo
|
injection volume of 0.5mL on Day 0
|
Active Comparator: Primary series of CoronaVac
participants who received primary vaccination of a CoronaVac at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
|
injection volume of 0.5mL on Day 0
|
Placebo Comparator: Primary series of CoronaVac (Placebo)
participants who received primary vaccination of a CoronaVac at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose Placebo
|
injection volume of 0.5mL on Day 0
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GMFR (Geometric Mean Fold Rise) of neutralizing antibody to SARS-CoV-2 measured by wild-type virus neutralization assay from baseline(Visit 2) to2 weeks post heterologous booster vaccinationfor each cohort
Time Frame: 2 weeks post heterologous booster vaccination for eachcohort
|
For all cohort
|
2 weeks post heterologous booster vaccination for eachcohort
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of solicited local/systemic Adverse Events(AEs)
Time Frame: Through 7 days post booster vaccination
|
For all cohort
|
Through 7 days post booster vaccination
|
Occurrence of unsolicited AEs
Time Frame: Through 28 days post booster vaccination
|
For all cohort
|
Through 28 days post booster vaccination
|
GMT of neutralizing antibody to SARS-CoV-2 measured by wild-type virus neutralization assay at each time point post heterologous booster vaccination.
Time Frame: Through Day 365 post vaccination
|
For all cohort
|
Through Day 365 post vaccination
|
GMFR of neutralizing antibody to SARS-CoV-2 measured by wild-type virus neutralization assay from baseline (Visit 2) to each subsequent time point post heterologous booster vaccination.
Time Frame: Through Day 365 post vaccination
|
For all cohort
|
Through Day 365 post vaccination
|
Percentage of participants with ≥4-fold rise in wild-type virus neutralizing antibody titer to SARS-CoV-2 from baseline (Visit 2) to each subsequent time point post heterologous booster vaccination.
Time Frame: Through Day 365 post vaccination
|
For all cohort
|
Through Day 365 post vaccination
|
GMT of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA at each time point post heterologous booster vaccination
Time Frame: Through Day 365 post vaccination
|
For all cohort
|
Through Day 365 post vaccination
|
GMFR of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA from baseline (Visit 2) to each subsequent time point post heterologous booster vaccination
Time Frame: Through Day 365 post vaccination
|
For all cohort
|
Through Day 365 post vaccination
|
Percentage of participants with ≥4-fold rise in ELISA SARS-CoV-2 RBD-binding IgG titer from baseline (Visit 2) to each subsequent time point post heterologous booster vaccination.
Time Frame: Through Day 365 post vaccination
|
For all cohort
|
Through Day 365 post vaccination
|
Occurrence of immediate systemic reactions in 30 minutes post heterologous booster vaccination.
Time Frame: Through 30 minutes post booster vaccination
|
For all cohort
|
Through 30 minutes post booster vaccination
|
Occurrence of SAEs, MAAEs, AEs leading to study withdrawal, and AESIs during the whole study period.
Time Frame: Through Day 365 post booster vaccination
|
Through 7 days post booster vaccination
|
Through Day 365 post booster vaccination
|
Cell-mediated response for both Th1 and Th2 cytokines measured by ELISpot and/or FluoroSpot, and for both CD4+ and CD8+ T-cells measured by FACS
Time Frame: Through Day 365 post vaccination
|
For all cohort (in a subset of participants)
|
Through Day 365 post vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Santa K Das, MD, Institute of Medicine (IOM).
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 9, 2022
Primary Completion (Actual)
August 22, 2023
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
August 11, 2022
First Submitted That Met QC Criteria
August 11, 2022
First Posted (Actual)
August 15, 2022
Study Record Updates
Last Update Posted (Actual)
September 7, 2023
Last Update Submitted That Met QC Criteria
September 6, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- GBP510_004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on GBP510 adjuvanted with AS03
-
SK Bioscience Co., Ltd.GlaxoSmithKline; Coalition for Epidemic Preparedness InnovationsActive, not recruitingCOVID-19 (Healthy Volunteers)Korea, Republic of
-
SK Bioscience Co., Ltd.GlaxoSmithKline; International Vaccine Institute; Coalition for Epidemic Preparedness...CompletedCovid19Thailand, Korea, Republic of, New Zealand, Philippines, Ukraine, Vietnam
-
Korea University Guro HospitalKorean Center for Disease Control and PreventionActive, not recruitingCOVID-19 (Healthy Volunteers)Korea, Republic of
-
SK Bioscience Co., Ltd.Coalition for Epidemic Preparedness InnovationsCompletedCOVID-19 (Healthy Volunteers)Korea, Republic of
-
PATHGlaxoSmithKline; Icahn School of Medicine at Mount Sinai; Duke University; Children... and other collaboratorsCompletedInfluenza | VaccineUnited States
-
Erasme University HospitalCompletedInfluenza | Rejection | Decreased Immunologic Activity [PE]Belgium
-
Sanofi Pasteur, a Sanofi CompanyGlaxoSmithKlineActive, not recruitingCOVID-19Honduras, United States, Australia, France, Kenya, Mexico, New Zealand, Panama, Spain, United Kingdom
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedLymphoma | Multiple Myeloma | Influenza A Virus, H1N1 SubtypeCanada
-
GlaxoSmithKlineRecruitingHepatitis BGermany, United Kingdom, Belgium
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Institut...CompletedMalaria,FalciparumBurkina Faso